Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 30, 2025
Reporting Period: Single event date (May 30, 2025)
Business Context: The Company entered into a Sales Agreement with Maxim Group LLC to facilitate an "at-the-market" offering of its common stock.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. The only financial figures disclosed relate to the terms of the new Sales Agreement:
- Maximum Offering Amount: $25,000,000 of common stock shares.
- Agent Commission: 3.0% of aggregate gross sales prices.
- Legal Fee Reimbursement (Execution): Up to $60,000.
- Legal Fee Reimbursement (Quarterly): Up to $7,500 per calendar quarter.
Material Changes
The primary material change is the execution of a definitive agreement on May 30, 2025, authorizing the Company to sell shares of common stock through an agent. This establishes a new mechanism for equity financing that was not in place prior to this date.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds from the offering, if any, are intended for working capital and general corporate purposes.
- Termination Rights: The agreement may be terminated by either the Company or the Agent at any time with ten business days' written notice, or immediately by the Agent under certain circumstances.
- Limitations: Sales are capped by the registered amount ($25 million), authorized unissued shares, Form S-3 limits, and prospectus supplement limits.
- Legal Disclaimer: The filing explicitly states it is not an offer to sell securities and that representations in the agreement are for the benefit of the parties only.
Investor Verification Checklist
- Verify the current number of authorized but unissued shares to ensure the $25 million cap is feasible.
- Review the effective shelf registration statement (File No. 333-268560) and the May 30, 2025 prospectus supplement for specific share pricing mechanisms.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.
- Assess the impact of the 3.0% commission and legal fees on the net capital raised.